Biotech Values

[TripleCutter]

This press release really got me thinking this morning. MNTA has many patents and pending patents around the analytics used to characterize heparins. This chain mapping one must be pretty important because I can't recall them doing a press release over a patent. What if there is no way to analytically characterize enox to FDA standard w out infringing on one of these patents? Teva could try to copy their science but would be infringing and couldn't get to market. Under this scenario the FDA could approve other generics but they couldn't get to market due to the IP.